ARTICLE | Targets & Mechanisms
ASCO readouts offer early hints of efficacy for 4-1BB antibodies
A trio of first-in-human readouts for 4-1BB agonistic antibodies point to clinical progress for the challenging checkpoint
May 26, 2021 12:15 AM UTC
LAG3 may be attracting most of the attention at ASCO21, but a trickle of first-in-human readouts for another checkpoint target — 4-1BB — suggests the broader landscape of checkpoint inhibitors could be reaching an inflection point.
At the American Society of Clinical Oncology virtual meeting, at least three companies will share first-in-human data on mAbs against 4-1BB, one of the checkpoint targets that previously stumbled in the clinic...